Boston Scientific Corporation (VIE:BSXC)
Austria · Delayed Price · Currency is EUR 77.80
+0.20 (0.26%)
At close: Jan 30, 2026
Boston Scientific Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 20,074 | 16,747 | 14,240 | 12,682 | 11,888 | |
Revenue Growth (YoY) | 19.87% | 17.61% | 12.29% | 6.68% | 19.92% |
Cost of Revenue | 6,267 | 5,290 | 4,391 | 4,003 | 3,760 |
Gross Profit | 13,807 | 11,457 | 9,849 | 8,679 | 8,128 |
Selling, General & Admin | 6,887 | 5,984 | 5,190 | 4,520 | 4,359 |
Research & Development | 2,052 | 1,615 | 1,414 | 1,323 | 1,204 |
Amortization of Goodwill & Intangibles | 897 | 856 | 828 | 803 | 741 |
Operating Expenses | 9,836 | 8,455 | 7,432 | 6,646 | 6,304 |
Operating Income | 3,971 | 3,002 | 2,417 | 2,033 | 1,824 |
Interest Expense | -349 | -305 | -265 | -470 | -341 |
Interest & Investment Income | - | 107 | 22 | 10 | 4 |
Currency Exchange Gain (Loss) | - | -16 | -41 | -31 | -27 |
Other Non Operating Income (Expenses) | 122 | -30 | -15 | -14 | -7 |
EBT Excluding Unusual Items | 3,744 | 2,758 | 2,118 | 1,528 | 1,453 |
Merger & Restructuring Charges | -101 | -16 | -69 | -24 | -40 |
Gain (Loss) on Sale of Investments | - | -79 | -59 | -1 | 250 |
Gain (Loss) on Sale of Assets | - | - | - | -22 | 78 |
Asset Writedown | -46 | -386 | -58 | -132 | -370 |
Legal Settlements | -194 | - | 111 | -173 | -430 |
Other Unusual Items | -18 | 5 | -58 | -35 | 136 |
Pretax Income | 3,385 | 2,282 | 1,985 | 1,141 | 1,077 |
Income Tax Expense | 493 | 436 | 393 | 443 | 36 |
Earnings From Continuing Operations | 2,892 | 1,846 | 1,592 | 698 | 1,041 |
Minority Interest in Earnings | 6 | 8 | 1 | - | - |
Net Income | 2,898 | 1,854 | 1,593 | 698 | 1,041 |
Preferred Dividends & Other Adjustments | - | 1 | 23 | 56 | 56 |
Net Income to Common | 2,898 | 1,853 | 1,570 | 642 | 985 |
Net Income Growth | 56.31% | 16.38% | 128.22% | -32.95% | - |
Shares Outstanding (Basic) | 1,480 | 1,472 | 1,453 | 1,431 | 1,422 |
Shares Outstanding (Diluted) | 1,495 | 1,486 | 1,464 | 1,440 | 1,434 |
Shares Change (YoY) | 0.58% | 1.53% | 1.65% | 0.41% | 1.21% |
EPS (Basic) | 1.96 | 1.26 | 1.08 | 0.45 | 0.69 |
EPS (Diluted) | 1.94 | 1.25 | 1.07 | 0.45 | 0.69 |
EPS Growth | 55.20% | 16.82% | 138.42% | -34.96% | - |
Free Cash Flow | - | 2,645 | 1,792 | 938 | 1,316 |
Free Cash Flow Per Share | - | 1.78 | 1.22 | 0.65 | 0.92 |
Gross Margin | 68.78% | 68.41% | 69.16% | 68.44% | 68.37% |
Operating Margin | 19.78% | 17.93% | 16.97% | 16.03% | 15.34% |
Profit Margin | 14.44% | 11.06% | 11.03% | 5.06% | 8.29% |
Free Cash Flow Margin | - | 15.79% | 12.58% | 7.40% | 11.07% |
EBITDA | 5,308 | 4,271 | 3,613 | 3,169 | 2,917 |
EBITDA Margin | 26.44% | 25.50% | 25.37% | 24.99% | 24.54% |
D&A For EBITDA | 1,337 | 1,269 | 1,196 | 1,136 | 1,093 |
EBIT | 3,971 | 3,002 | 2,417 | 2,033 | 1,824 |
EBIT Margin | 19.78% | 17.93% | 16.97% | 16.03% | 15.34% |
Effective Tax Rate | 14.56% | 19.11% | 19.80% | 38.82% | 3.34% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.